BACKGROUND: Resting heart rate (RHR) is considered as a strong predictor of total mortality and hospitalization due to heart failure in hypertension patients. Bisoprolol fumarate, a second-generation beta-adrenoreceptor blockers (β-blocker) is commonly prescribed drug to manage hypertension. The present study was to retrospectively evaluate changes in the average RHR and its association with cardiovascular outcomes in bisoprolol-treated coronary artery disease (CAD) patients from the CAD treated with bisoprolol (BISO-CAD) study who had comorbid hypertension. METHODS: We performed ad-hoc analysis for hypertension sub-group of the BISO-CAD study (n = 866), which was a phase IV, multination, multi-center, single-arm, observational study carried out from October 2011 to July 2015 across China, South Korea, and Vietnam. Multivariate regression analysis was used to identify factors associated with incidence of composite cardiac clinical outcome (CCCO), the results were presented as adjusted odds ratio (OR) along with 95% confidence interval (CI) and adjusted P value. RESULTS: A total of 681 patients (mean age: 64.77 ± 10.33 years) with hypertension from BISO-CAD study were included in the analysis. Bisoprolol improved CCCOs in CAD patients with comorbid hypertension, with RHR <65 and <70 beats/min compared with RHR ≥65 and ≥75 beats/min, respectively, in the efficacy analysis (EA) set. In addition, it lowered RHR in both intent-to-treat (ITT) and EA groups after 6, 12, and 18 months of treatment. Further, RHR 70 to 74 beats/min resulted in significantly higher risk of CCCOs EA set of patients (adjusted OR: 4.34; 95% CI: 1.19-15.89; P = 0.03). Also, events of hospitalization due to acute coronary syndrome were higher when RHR 69 to 74 beats/min compared to RHR <69 beats/min in ITT patients. CONCLUSION Bisoprolol can effectively reduce RHR in Asian CAD patients with comorbid hypertension and hence, improve CCCO without affecting their blood pressure.

Background: In Vietnam, there are a number of studies on the application of ATRA in treating acute promyelocytic leukemia (AML \u2013 M3) but they have still faced with certain difficulties. Objectives: (1). Study PML/RAR alpha fusion gene on the patients diagnosed with AML \u2013 M3. (2). Study the index of hematology of the PML/RAR alpha positive group. Subject and Method: 21 patients with acute promyelocytic leukemia (M3) were studied. All patients were examined with morphology, coagulation and cytogenetic tests and RNA were extracted from leukemic cells and PCR for PML/RAR alpha fusion transcript. Result and conclusion: PML/RAR alpha positive in 67% including 4 patients which were not discovered t(15; 17) by cytogenetic technique. Rates of three subtype (bcr1, bcr2 and bcr3) of PML/RAR alpha were 7 patients (50%), 3 patients (21,5%) and 4 patients (28,5%), respectively. WBC and bone marrow cells of PML/RAR alpha positive group were 5.08+/-3.87 and 155.82+/-106.21. D \u2013 Dimer level was 1954.89+/-1575.28; 93% of patients in the PML/RAR alpha positive group had DIC.
Acute promyelocytic leukemia ; M3 ; PML/RAR alpha

Background: Chromosome mutation type t(8;21) has quite a high frequency in acute myelogenous leukemia, which accounted for about 15% among adult patients. From 2001, the WHO has a new classification for acute myelogenous leukemia based on genetic mutations. Form had AML1/ETO were arranged into genetic mutation group with better prognosis and ability to fully recover after chemotherapy with a high dose of cytarabin. Objective: Study AML1/ETO fusion gene on the patients diagnosed with Acute Myelogenous Leukemia (AML), as well as the clinical features and some haematologic parameters of the AML1/ETO positive group. Subject and methods: 76 patients with AML were treating in the National Institute of Hematology & Blood Transfusion and the Department of Hematology & Blood Transfusion of Bach Mai Hospital from April 2007 to July 2008. These patients were studied for clinical examination, morphology and RNA were extracted from leukemic cells and PCR for AML1/ETO fusion transcript was performed. Results and conclusions: The incidence of AML1/ETO positive in the AML patients was 24%. The incidence of AML1/ETO positive in AML-M2 was 28%. In the AML1/ETO positive group: median age was 26.94+/-9.22; rate of severe anemia, hemorrhage, fever, infection, hepatomegaly, splenomegaly, lymphadenopathy and gum hypertrophy was 44%, 33%, 28%, 11%, 44%, 28%, 17% and 6%, respectively. Median hemoglobin, WBC, platelet, bone marrow cell count, % blast in peripheral blood and in bone marrow was 84.41+/-28.97 g/l, 29.42+/-31.36 g/l, 42.12+/-33.83 g/l, 215.93+/-134.42 g/l, 56.21+/-26.58% and 65.14+/-16.12%, respectively.
acute myelogenous leukemia ; AML1/ETO fusion gene

Background: In Vietnam, there are increase rate of patients with acute leukemia including acute myelogenous leukemia. The clinical, gender, age as well as morphological characteristics of cells have prognostic significance about response to treatment and survival time of patients. Objectives: (1) To describe the distribution of acute myelogenous leukemia types by FAB standard in 'National Institute of Hematology and Blood Transfusion. (2) To describe the clinical characteristics of patients with acute myelogenous leukemia. Subjects and methods: The study included 67 patients diagnosed acute myelogenous leukemia by FAB standard without chemotherapy in 'National Institute of Hematology and Blood Transfusion. Results and conclusions: The median age: 35.55 \xb1 13.46, sex: 53% male, 47% female. Ratio of M0, M1, M2, M3, M4, M5, M6, M7 was 1, 10, 19, 18, 30, 13, 6, 1 %, respectively. 100% of these patients presented with anemia, 57 % with hemorrage, 46 % with fever. Lymphadenopathy was presented in 61 %, hepatomegaly was presented in 27% and spleenomegaly was presented in 9%. 53% of the patients had more bleeding was M3. Lymphadenopathy, hepatospleenomegaly had most frequently seen in the patients of M4 and M5 type. \r\n", u'\r\n', u'
Leukemia ; Myeloid ; Acute/ immunology ; Hematology

Background: Bcr/abl fusion gene plays an important role in diagnosing and treating chronic myelogenous leukemia. Objective: to detect fusion genes: b3a2, b2a2, b3a3, b2a3 and e1a2 in patients with chronic myelogenous leukemia by using Nested RT - PCR technique. Subjects and methods: Peripheral blood samples were analyzed by Nested RT - PCR assay from 30 adult patients. Results: 28/30 patients showed bcr/abl fusions gene; among them 20/30 patients showed b3a2 fusions gene, 5/30 patients showed b2a2 fusions gene, 2/30 patients showed co-expression of the b3a2 and b2a2. 1/30 showed e1a2; 2/30 patients showed negative fusion gene. Count of leukocytes and platelets of patients with b3a2 fusion genes were 311.3 G/l and 597.5 G/l, respectively and of patients with b2a2 fusion genes were 136.7 G/l and 333 G/l, respectively. Conclusion: Most of patients showed b3a2 fusion gene, while remaining showed b2a2 transcripts or the co-expression of the b3a2, only one case showed e1a2 fusion gene, two patients showed negative fusion gene. There was no case which showed b3a3 or b2a3 fusion gene. Nested RT assay should be used to determine bcr/abl fusion genes for patients with chronic myelogenous leukemia\r\n', u'\r\n', u'
Leukemia ; Myelogenous ; Chronic ; BCR-ABL Positive/ blood ; pathology

Background: Detection of BCR/ABL fusion gene has important significance in diagnosing and monitoring response to therapy in chronic myeloid leukemia. Objective: Application of FISH (Fluorescence In Situ Hybrydization) technique for detection of abl/bcr fusion gene in chronic myelogenous leukemia. Subjects and methods: The study included 10 patients of chronic myelogenous leukemia diagnosed by methods of morphology and cell chemistry. Peripheral blood and bone marrow samples of them were analyzed Philadelphia (Ph1) chromosome by cytogenetic technique. Among them, 5 patients were tested by FISH technique on the slide of interphase and remainders were tested by FISH technique on the slide of metaphase cell. Results: Results of analyzing chromosome of 10 patients showed that 8 patients had Ph1 chromosome. 2 patients without Ph1 chromosome were patients who had not high of leukocyte count: 28x109leukocyte/l and 36x109leukocyte/l, respectively. In the FISH on the slide of interphase, all 5 patients had Ph1 chromosome and abl/bcr fusion gene. In the FISH on the slide of metaphase cell, 3 patients had Ph1 chromosome and abl/bcr fusion gene. Conclusion: FISH technique has been applied successfully to detect ABL/BCR gene in patients with chronic myelogenous leukemia.\r\n', u'\r\n', u'
Leukemia ; Myelogenous ; Chronic ; BCR-ABL Positive/ pathology

Background: Normally, gender of human is indentified according to enternal sexual organ. However in several cases the patient\u2019s gender is not able to identify based on enternal sexual organ. In these cases test for gender identification is need. Objectives: Identify relationship between clinical condition of the external sexual organ and sexual chromosome. Subjects and method: 119 patients with diagnosis of \u201cunclear gender identification\ufffd?made by hospitals in Ha noi. Culture of peripheral blood, analyze sexual chromosome, comparing with gender indentification proposed in neonatal period and gender indentified by physical at time of examination. Results: 87/119 cases (73,11%) have male sexual chromosome. According of gender proposed in neonatal period to sexual chromosome are 76,90% for children considered \u201cboy\ufffd?and only 33,33% for \u201cgirl\ufffd? The according percentage is higher at time of examination (mean age is 6,4 years old). There are 4 cases of female phenotype with XY sexual chromosome. Conclusion: In cases with unclear gender identification in neonatal period: 73,11% cases have male sexual chromosome (XY). Apprasal gender at neonatal period is difficulty accurate, especialy for children considered girl (the according rate is only 33,33%). \ufffd?Detect 4 cases of \u201ctesticular femiuization\ufffd?
Sex Chromosomes ; Gender Identity ;

Background: Anti \ufffd?HLA (Human Leukocyte Antigen) antibody is result of immunization in allotransplantation. Organ transplantation is one of the great scientific achievements of the medicine. However, it is difficult to have the perfect harmony of HLA group. Inevitable consequence is the graft will be eliminated by the immune process. In Vietnam, organ transplantation was a relatively new specialty and there was not much research on evaluation immune process after transplantation. Objectives: To determine the rate of present of anti \ufffd?HLA antibody on transplant patients, and the role of post \ufffd?transplant anti \ufffd?HLA antibodies on long \ufffd?term graft function. Subjects and method: ELISA technique was used to analysis 31 blood samples of 31 patients who were transplanted organs at 103 military hospital and Cho Ray hospital from May 2000 to July 2007. This was a retrospective and described cross-sectional study on theclinical records. Results:The rate of anti \ufffd?HLA antibodies was 35.5%. The present of anti \ufffd?HLA antibodies of transplant patients had negative impact on graft function. Conclusion: The detection of anti \ufffd?HLA antibodies by ELISA in the post transplant period may be a high confident and sensitive technique for follows up graft function.
Organ Transplantation/ contraindications ; HLA Antigens ; Antibodies ; Enzyme-Linked Immunosorbent Assay ;

Background: The reduction of erythrocytes from cord blood is very need for long - term storage of C034 cells for transplantation. Reduced erythrocyte will reduces preservative blood volume, preservatives and freely HST when defrosting, so stem cells are better protected. Objectives: To study selection of the best centrifugal procedure to reduce maximal erythrocytes and lose minimal C034 cells from cord blood. Subjects and methods: 20 blood samples selected from 60 cord blood units was used for this study. The study was carried out through two steps. In the first step, the centrifugal speed was fixed and the centrifugal time was changed.In the second step, the centrifugal time was fixed, the centrifugal speed was changed. From collected results the best appropriate procedure to reduce erythrocytes from cord blood have been selected. Results: The procedure of gradient centrifuge with speed of 500g in 6 minutes isolated> 50% of erythrocytes, kept > 84% of CD34 cells and then centrifuge of 1000 g in 10 minutes reduced about 40% of volume of nuclear cell - suspension. Conclusion: The procedure can use for preparation of stem cell suspension from cord blood to storage in nitrogen liquid. \r\n', u'\r\n', u'
Erythrocytes/ pathology ; Fetal Blood/ chemistry ; drug effects ; immunology

Background: In recent years, Vietnam has applied four methods (morphology, cell chemistry, immune marker classification, cyto genetic) in diagnosis and used multi-chemotherapy in treatment for acute myelogenous leukemia (AML)\r\n', u'Objectives: To initially determine some fusion gene transcripts in the acute myelogenous leukemia patients by applying PCR technique. Subject and method: The study included 19 patients with acute myelogenous leukemia treated in National Institute of Hematology and Blood Transfusion and Bachmai Hospital from April 2007 to August 2007. RNA were extracted from leukemic cells and PCR for AML1/ETO, CBFP/MYH11, PMR/RARa fusion transcript was done. Results: Number of male patients was 6 (32%), female patients was 13 (68%). The average age of these patients was 32.67 \xb113.62. There were three M4, M4eo patients with AML1/ETO gene (accounting for 16%), two M2, M4 patients with CBF/MYH1 gene and type F of genetic modification accounting for 11%), two M3 patients with PMR/RAR\u03b1 and Bcr3 of genetic modification (accounting for 11%). Conclusion: Results of the study did not differ significantly from other researches in the world. This study showed the need of applying the PCR technique in determining fusion gene transcript together with traditional cyto-genetic method.\r\n', u'\r\n', u'
Leukemia ; Myeloid ; Acute/ blood ; pathology ; complications ; Polymerase Chain Reaction